Article Text

Download PDFPDF
Antithrombotic treatment in atrial fibrillation
  1. G Y H Lip,
  2. C J Boos
  1. Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
  1. Correspondence to:
    Professor Gregory Y H Lip
    Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK; g.y.h.lip{at}bham.ac.uk

Footnotes

  • Published Online First 13 September 2005

  • Competing interests: GL has received funding for research, educational symposia, consultancy and lecturing from different manufacturers of drugs used for the treatment of atrial fibrillation and thrombosis. He is Clinical Adviser to the Guideline Development Group writing the United Kingdom National Institute of Clinical Excellence (NICE) Guidelines on atrial fibrillation management (www.nice.org.uk).

View Full Text

Statistics from Altmetric.com

View Full Text

Footnotes

  • Published Online First 13 September 2005

  • Competing interests: GL has received funding for research, educational symposia, consultancy and lecturing from different manufacturers of drugs used for the treatment of atrial fibrillation and thrombosis. He is Clinical Adviser to the Guideline Development Group writing the United Kingdom National Institute of Clinical Excellence (NICE) Guidelines on atrial fibrillation management (www.nice.org.uk).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society
  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society
  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society